Search Result

Results for "

antifungal mechanisms

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (1) Autophagy (1) Cytochrome P450 (1) Drug Intermediate (1) EBV (1) Ferroptosis (3) Fungal (17) Herbicide (1) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) NF-κB (1) PKA (1) Ras (1) Reference Standards (1) SARS-CoV (1) Succinate Dehydrogenase (1)
By Research Areas:	Cancer (4) Infection (17) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100579

Ferrostatin-1 Maximum Cited Publications 1548 Publications Verification Fer-1	Ferroptosis Fungal	Cancer
Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC₅₀=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .

HY-18233

Manogepix 4 Publications Verification E1210; APX001A	Fungal	Infection
Manogepix (E1210) is a first-in-class, broad-spectrum and orally active antifungal. Manogepix has a mechanism of action-inhibition of fungal glycosylphosphatidylinositol (GPI) biosynthesis .

HY-N2389

Formosanin C 5 Publications Verification	Apoptosis Autophagy Ferroptosis NF-κB Fungal	Infection Inflammation/Immunology Cancer
Formosanin C is a diosgenin saponin with multiple biological activities. Formosanin C possesses multiple anti-tumor mechanisms, including inducing apoptosis and autophagy, blocking the cell cycle, inhibiting metastasis and inducing ferroptosis. Formosanin C can inhibit the NF-κB signaling pathway to exert anti-inflammatory effects, and enhance the activity of immune cells. Formosanin C exhibits the inhibiting effect against C. albicans. Formosanin C can be used for the study of anti-inflammation, antifungal anti and anti-cancer (including lung cancer, liver cancer, breast cancer and colorectal cancer, etc.) .

HY-132191

Pradimicin A	Fungal SARS-CoV HIV	Infection
Pradimicin A is a potent antifungal agent with a minimum inhibitory concentration (MIC) of 4 μg/mL against Candida rugosa. Pradimicin A exhibits antiviral activity against SARS-CoV, human immunodeficiency virus (HIV) and other enveloped viruses. Pradimicin A exerts its fungicidal activity through a Ca ²⁺-dependent mechanism, which induces *fungal* lysis. Pradimicin A can be used in research related to fungal infections, HIV infections and COVID-19 .

HY-N2620

Rutaevin	Cytochrome P450	Infection
Rutaevin is an antifungal toxin and CYP3A4 inactivator. Rutaevin requires NADPH-dependent bioactivation to generate cis-but-2-ene-1,4-dial, which then covalently modifies and mechanism-based inactivates human CYP3A4 (IC₅₀=4.48 μM, K_i=15.98 μM), and interacts with substances such as glutathione. Rutaevin disrupts the cellular structure of Sirococcus conigenus, accumulates linearly in resistant larch after pathogen exposure, and induces liver toxicity in mice via oral administration. Rutaevin can be applied to research in fields related to larch shoot blight and other associated areas .

HY-156090

PK-10	Mitochondrial Metabolism Fungal	Infection
PK-10 is a synergistic antibacterial agent of Fluconazole (HY-B0101) and has strong antifungal activity against a variety of Fluconazole-resistant Candida albicans strains. PK-10 combined with Fluconazole can inhibit hyphae formation and induce the accumulation of reactive oxygen species. It further causes damage to mitochondrial membrane potential, reduces intracellular ATP content, and leads to mitochondrial dysfunction .

HY-163911

SDH-IN-19	Fungal Antibiotic	Infection
SDH-IN-19 (compound A13) is a fungicide, with an EC₅₀ value of 0.83 μg/mL against Rhizoctonia solani. SDH-IN-19 can be used in antifungal research of crops .

HY-158321

SDH-IN-15	Fungal Succinate Dehydrogenase	Infection
SDH-IN-15 (Compound 5e) is an inhibitor of succinate dehydrogenase (SDH) (IC₅₀=2.04 μM). SDH-IN-15 has significant antifungal activity. SDH-IN-15 blocks the mitochondrial respiratory chain of the fungus through inhibition of SDH, resulting in fungal death .

HY-124250

9-OxoOTrE 9-KOTrE	Fungal	Infection
9-OxoOTrE (9-KOTrE) is an antifungal agent against B. cinerea, C. herbarum, P. infestans, and P. parasitica, through a mechanism based on their electrophilic nature .

HY-149067

Antifungal agent 47	Fungal	Infection
Antifungal agent 47 (compound 3b) shows the highest and broad-spectrum fungicidal activity, strong respiratory inhibition activity, and adenosine 5′-triphosphate synthesis inhibition activity. Antifungal agent 47 is potential as a fungicide .

HY-N12497

Moracin B	Fungal	Infection
Moracin B is a phytoalexin with antifungal activity. Moracin B can be isolated from the cortex and phloem tissues of mulberry (Morus alba Linne) infected with Fusarium solani f. sp. mori. Moracin B can be used to study plant disease resistance mechanisms against microbial infections, particularly showing potential application value in the field of plant disease control .

HY-170974

SDH-IN-20	Fungal	Infection
SDH-IN-20 (compound A19) is an antifungal agent. SDH-IN-20 against Verticillium dahlia, R. solani with EC₅₀s of less than 3.0 μg/mL, 2.87 μg/mL. SDH-IN-20 exerts its highly antifungal effects by acting as an effective succinate dehydrogenase (SDH) inhibitor with an IC₅₀ of 29.33 μM. SDH-IN-20 adversely impacts the integrity of cell membranes and mycelial morphologies of R. solani .

HY-N19777

Glochidioboside	Fungal	Infection
Glochidioboside, a neolignan glucoside found in Sambucus williamsii, is an *antifungal* agent. Glochidioboside induces membrane depolarization, membrane permeabilization, and pore formation on fungal membranes. Glochidioboside exerts an antifungal activity through a membrane-disruptive mechanism .

HY-179518

Antifungal agent 140	Fungal PKA Ras	Infection
Antifungal agent 140 (compound 5p) is a potent *antifungal* agent with broad-spectrum antifungal activity. Antifungal agent 140 exerts a dual mechanism by targeting the Ras/cAMP/PKA pathway to inhibit hyphal formation and the ergosterol biosynthesis pathway. Antifungal agent 140 enhances survival, reduces fungal load in the kidneys, and strengthens host immune responses in a murine model of systemic candidiasis. Antifungal agent 140 can be used for research of resistant fungal infections .

HY-N18128

Hunnemanine	Fungal	Infection
Hunnemanine is a protoberberine-type isoquinoline alkaloid with significant antifungal activity. At a concentration of 1000 ppm, Hunnemanine completely inhibits spore germination of a variety of phytopathogenic fungi, including Alternaria brassicae, Helminthosporium pennisetti, and Fusarium lini. Hunnemanine can be applied to studies on the infection mechanisms of phytopathogenic fungi and related control strategies .

HY-18233S

Manogepix-d4 E1210-d₄; APX001A-d₄	Isotope-Labeled Compounds Fungal	Infection
Manogepix-d₄ (E1210-d₄) is the deuterium labeled Manogepix (HY-18233). Manogepix (E1210) is a first-in-class, broad-spectrum and orally active antifungal. Manogepix has a mechanism of action-inhibition of fungal glycosylphosphatidylinositol (GPI) biosynthesis .

HY-179411

Antifungal agent 139	Fungal	Infection
Antifungal agent 139 (Compound li) is an antifungal agent that exhibits antifungal activity against Colletotrichum gloeosporioides by inhibiting CgSfu1 and CgRidA. Antifungal agent 139 completely inhibits mycelial growth, spore germination, and appressorium formation, with an EC₅₀ of 18 μg/mL. Antifungal agent 139 can completely block the pathogen's infection of host plants (such as linden trees, cypress trees). Antifungal agent 139 can be used for research on anthrax .

HY-183552

mCPX	HIF/HIF Prolyl-Hydroxylase EBV Drug Intermediate	Infection Cancer
mCPX is a prodrug of the antifungal agent Ciclopirox olamine (CPX) (HY-B0450A). CPX exhibits bacteriostatic and iron-chelating activities, while mCPX enhances the iron stability of CPX. mCPX inherits the core mechanism pathway of CPX and can induce EBV lytic reactivation in EBV ⁺ gastric cancer cells via the hypoxia pathway (HIF‑1α). mCPX is applicable to research related to EBV-positive gastric cancer .

HY-100579R

Ferrostatin-1 (Standard) Fer-1 (Standard)	Ferroptosis Reference Standards Fungal	Cancer
Ferrostatin-1 (Standard) is the analytical standard of Ferrostatin-1 (HY-100579). This product is intended for research and analytical applications. Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC50=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .

HY-N16818

9-epi-Blumenol C	Herbicide	Others
9-epi-Blumenol C is a C13-norisoprenoid (carotenoid derivative) compound with allelopathic and *antifungal* activities, and can regulate plant growth. The IC₅₀ values ??of 9-epi-Blumenol C for watercress roots and hypocotyls are 2780 μM and 2240 μM, respectively, and for perennial ryegrass roots and coleoptiles are 3290 μM and 2950 μM, respectively. 9-epi-Blumenol C exhibits allelopathic activity through a mechanism involving direct inhibition of plant growth and degradation of arbuscular mycorrhizal fungi (AMF) colonization, thereby weakening nutrient uptake and stress resistance in neighboring plants. 9-epi-Blumenol C can be used in herbicide development and research related to plant competition mechanisms. 9-epi-Blumenol C can be obtained from the dried fallen leaves of Metasequoia glyptostroboides (a plant of the cypress family, genus Metasequoia) through extraction with 70% methanol and purification by ethyl acetate extraction .

Cat. No.	Product Name

HY-L938

Antifungal Lead-like compound library	8350 compounds
Currently,the incidence and mortality rates of clinical fungal infections remain high. Existing antifungal drugs are limited in variety and associated with numerous adverse effects, creating an urgent demand for the development of novel antifungal agents. Antifungal compound libraries can support the screening and development of new antifungal drugs. The mechanisms of action of antifungal drugs cover key processes such as fungal cell membrane synthesis, cell wall synthesis, and cell division. They exert fungicidal or fungistatic effects by specifically targeting different molecular pathways. This library includes a variety of core analogs of antifungal drugs, making it adaptable to antifungal research in diverse scenarios. It can be used for the high-throughput screening of novel antifungal drug candidates, enabling the rapid identification of compounds with potential antifungal activity and facilitating the elucidation of drug-target interactions and resistance mechanisms. Additionally, it supports the screening of compounds and combinations that reverse drug resistance, thereby uncovering the novel antifungal potential of existing compounds. The library comprises 8350 compounds with a well-defined screening strategy. The core sources of the compounds include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6 MCE has collected more than 500 antifungal molecules.All screened compounds conform to lead-like physicochemical properties, exhibiting both structural diversity and drug-like characteristics, and providing valuable support for the research and development of novel antifungal drugs.

Antifungal Lead-like compound library

8350 compounds

Currently,the incidence and mortality rates of clinical fungal infections remain high. Existing antifungal drugs are limited in variety and associated with numerous adverse effects, creating an urgent demand for the development of novel antifungal agents. Antifungal compound libraries can support the screening and development of new antifungal drugs.

The mechanisms of action of antifungal drugs cover key processes such as fungal cell membrane synthesis, cell wall synthesis, and cell division. They exert fungicidal or fungistatic effects by specifically targeting different molecular pathways. This library includes a variety of core analogs of antifungal drugs, making it adaptable to antifungal research in diverse scenarios. It can be used for the high-throughput screening of novel antifungal drug candidates, enabling the rapid identification of compounds with potential antifungal activity and facilitating the elucidation of drug-target interactions and resistance mechanisms. Additionally, it supports the screening of compounds and combinations that reverse drug resistance, thereby uncovering the novel antifungal potential of existing compounds.

The library comprises 8350 compounds with a well-defined screening strategy. The core sources of the compounds include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6 MCE has collected more than 500 antifungal molecules.All screened compounds conform to lead-like physicochemical properties, exhibiting both structural diversity and drug-like characteristics, and providing valuable support for the research and development of novel antifungal drugs.

HY-L048

Antifungal Compound Library	551 compounds
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc. MCE offers a unique collection of 551 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Antifungal Compound Library

551 compounds

The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc.

MCE offers a unique collection of 551 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

HY-L939

Antibacterial Lead-like compound library	10855 compounds
The rising prevalence of multidrug-resistant and extensively drug-resistant bacteria, combined with emerging resistance mechanisms and the limitations of existing antibacterial drugs, creates an urgent need for novel antibacterial agents. Antibacterial compound libraries serve as key tools to support antibacterial drug screening and development. This library features structurally diverse compounds, including small-molecule scaffolds and natural product derivatives, and exhibits diverse antibacterial mechanisms of action. For example, these compounds exert antibacterial effects by disrupting bacterial cell structures, interfering with bacterial metabolic processes, and inhibiting nucleic acid synthesis. The derivation of scaffold structures enhances their activity against drug-resistant bacteria and their selectivity against different types of bacteria. This library can be used for the high-throughput screening of novel antibacterial drug candidates and the identification of potent compounds against drug-resistant and multidrug-resistant bacteria. Additionally, it provides a reference for compound structural modification, enabling further in-depth research on the structure-activity relationships(SARs) of antibacterial drugs. It can also be applied to the exploration of bacterial resistance mechanisms and reversal strategies, as well as the discovery of antibacterial molecules that inhibit efflux pumps and restore drug susceptibility. The library contains 10855 structurally diverse drug-like compounds. Its core compound sources include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6. MCE has collected more than 1900 antibacterial molecules. All screened compounds conform to lead-like physicochemical properties, providing valuable support for the research and development of novel antibacterial drugs.

Antibacterial Lead-like compound library

10855 compounds

The rising prevalence of multidrug-resistant and extensively drug-resistant bacteria, combined with emerging resistance mechanisms and the limitations of existing antibacterial drugs, creates an urgent need for novel antibacterial agents. Antibacterial compound libraries serve as key tools to support antibacterial drug screening and development.

This library features structurally diverse compounds, including small-molecule scaffolds and natural product derivatives, and exhibits diverse antibacterial mechanisms of action. For example, these compounds exert antibacterial effects by disrupting bacterial cell structures, interfering with bacterial metabolic processes, and inhibiting nucleic acid synthesis. The derivation of scaffold structures enhances their activity against drug-resistant bacteria and their selectivity against different types of bacteria. This library can be used for the high-throughput screening of novel antibacterial drug candidates and the identification of potent compounds against drug-resistant and multidrug-resistant bacteria. Additionally, it provides a reference for compound structural modification, enabling further in-depth research on the structure-activity relationships(SARs) of antibacterial drugs. It can also be applied to the exploration of bacterial resistance mechanisms and reversal strategies, as well as the discovery of antibacterial molecules that inhibit efflux pumps and restore drug susceptibility.

The library contains 10855 structurally diverse drug-like compounds. Its core compound sources include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6. MCE has collected more than 1900 antibacterial molecules. All screened compounds conform to lead-like physicochemical properties, providing valuable support for the research and development of novel antibacterial drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure